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Abstract
The rate of response to pharmacological treatment in Obsessive-compulsive disorder (OCD) oscillates between 40 and
70%. Genetic and environmental factors have been associated with treatment response in OCD. This study analyzes the
predictive ability of a polygenic risk score (PRS) built from OCD-risk variants, for treatment response in OCD, and the
modulation role of stressful life events (SLEs) at the onset of the disorder. PRSs were calculated for a sample of 103
patients. Yale–Brown Obsessive Compulsive Scale (YBOCS) scores were obtained before and after a 12-week treatment.
Regression analyses were performed to analyze the inﬂuence of the PRS and SLEs at onset on treatment response. PRS
did not predict treatment response. The best predictive model for post-treatment YBOCS (post YBOCS) included basal
YBOCS and age. PRS appeared as a predictor for basal and post YBOCS. SLEs at onset were not a predictor for treatment
response when included in the regression model. No evidence for PRS predictive ability for treatment response was
found. The best predictor for treatment response was age, agreeing with previous literature speciﬁc for SRI treatment.
Suggestions are made on the possible role of neuroplasticity as a mediator on this association. PRS signiﬁcantly
predicted OCD severity independent on pharmacological treatment. SLE at onset modulation role was not evidenced.
Further research is needed to elucidate the genetic and environmental bases of treatment response in OCD.
Background
Obsessive-Compulsive Disorder (OCD) is a complex
neuropsychiatric condition that may interfere severely in
the patient’s life and lead to maladaptive behavior1,2.
Lifetime prevalence of the disorder is 2–3%3. Treatment
usually consists of medication and cognitive-behavioral
therapy, as recommended in OCD clinical guidelines4.
Selective serotonin reuptake inhibitors (SSRIs) comprise
the ﬁrst-line pharmacological treatment for OCD.
However, treatment response is variable, with the pro-
portion of OCD patients that improve with pharmacolo-
gical treatment oscillating between 40 and 70%, and in
some cases only a partial response is obtained5. Non-
responders may be treated with another SSRI6, with
antipsychotics as adjunctive treatment7, or clomipramine
either as monotherapy or as a coadjuvant8.
Several studies have examined the genetic and envir-
onmental factors associated with treatment response in
OCD. Genetic variants in catecholaminergic (HTR2A,
HTR1B, SLC6A4, COMT), glutamatergic (SLC1A1,
GRIN2B, DLGAP2, SLITRK5, DLGAP1), and neuro-
trophic (BDNF) systems have been associated with
response to SSRIs9–13. Some, but not all, of these genes
have been related to increased risk of developing OCD
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(BDNF14–16, SLC1A117, COMT18, SLC6A419). Meanwhile,
pharmacokinetic studies have also associated variants of
an enzyme from the cytochrome P450 family (CYP2D6)
with response to SSRIs and non-selective serotonin
reuptake inhibitors (SRIs)20,21. Besides candidate gene
association studies, a genome-wide association study
(GWAS) has been carried out to study SSRI response in
OCD. Although only one variant (located near the DISP1
gene) met the genome-wide signiﬁcance level, other 41
presented indications of association; most of these var-
iants played a role in the glutamatergic and serotonergic
pathways22. These results suggest that genetic factors may
inﬂuence treatment response in OCD.
GWAS data can also be used to generate an important
index known as the polygenic risk score (PRS), a measure
of an individual’s genetic risk conferred by common
variants of the studied trait. Based on the results of a
GWAS discovery sample, it is calculated as the sum of the
number of risk alleles carried by an individual, weighted
according to their effect23,24.
The association between a PRS and treatment response
has been analyzed in several psychiatric conditions,
including affective disorders and schizophrenia25. In the
case of SSRI response, inconsistent data have been
reported for affective disorders. As an example,
researchers involved in the GENDEP, STAR*D, and
MARS projects constructed a PRS for antidepressant
response derived from a meta-analysis of GENDEP and
MARS participants. This PRS accounted for up to 1.2% of
response variance in the STAR*D sample26. Conversely,
García González et al27. constructed a PRS for treatment
response in major depressive disorder (MDD) using
pharmacogenetic samples from the GENDEP and
STAR*D studies, but found no signiﬁcant associations. To
the best of our knowledge, PRS methodology has not been
employed to study treatment response in OCD.
Stressful conditions have also been observed to inﬂu-
ence treatment response in several mental disorders. One
of the most extensively studied of these is childhood
abuse, which has been associated with treatment response
in depression28–31 and social anxiety disorder32. A history
of trauma has also been related to greater treatment
resistance in OCD33. Conversely, Shavitt et al34. found
that OCD patients reporting trauma beneﬁted more from
SSRI treatment than those who did not. Further research
has investigated the inﬂuence of gene–environment
interaction (GxE) on treatment response. Thus, it has
been reported that response to SSRIs in affective disorders
is inﬂuenced by the interaction between non-traumatic
but stressful life events (SLEs) and variants of the
SLC6A435, BDNF and ST8SIA (a gene involved in neu-
roproliferation and neuroplasticity) genes36. In addition, a
gene associated with the catecholamine system (SLC6A2)
has been related to treatment response in MDD, through
an interaction with childhood abuse37. Finally, a GxE
inﬂuence on treatment response has also been described
in OCD for variants of the glutamatergic gene SLC1A1
and SLEs at onset of the disorder12. However, none of
these studies has made use of a PRS.
Given the above, the objective of this study was to
analyze how genes inﬂuence treatment response in OCD,
and how this inﬂuence may be modulated by certain
environmental conditions. We hypothesized that a PRS
built for OCD would predict treatment response to SRIs
and that this association would be modulated by SLEs at
onset of the disorder.
Methods
Subjects
Our study sample comprised 103 Spanish Caucasian
patients (46 females; mean age 33.23 ± 9.66) recruited
from the OCD clinic at Bellvitge Hospital (Barcelona,
Spain). All participants met the DSM-IV criteria for OCD
diagnosis38, with a duration of at least one year. Diagnoses
were independently assigned by two psychiatrists with
extensive clinical experience in OCD, each of whom
interviewed the patients separately using the Structured
Clinical Interview for DSM-IV Axis I Disorders-Clinician
Version (SCIDCV)39. Patients were offered treatment at
our clinic with a SRI (SSRI or clomipramine), considering
their history of previous medication and preference.
Maximum recommended doses were administered to the
patients for a minimum period of 12 weeks. Exclusion
criteria consisted of presenting psychoactive substance
abuse/dependence (either current or in the past six
months), psychotic disorders, intellectual disability, severe
organic or neurological pathology except tic disorder, and
autism spectrum disorder. Other affective and anxiety
disorders were not considered criteria for exclusion if
OCD was the main diagnosis.
After receiving a full description of the study, patients
were required to give their written informed consent. This
study was performed in accordance with the Helsinki
Declaration of the World Medical Association, and
approved by the Ethical Committees of Bellvitge Hospital.
Clinical assessment
Participants’ sociodemographic and clinical character-
istics and medical data were collected in structured
interviews during their ﬁrst visit to our unit. Age at onset
was deﬁned as the moment when obsessive symptoms
reached a clinically signiﬁcant level. Baseline severity of
the obsessive and compulsive symptoms was assessed
through the clinician-administered version of the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS)40. The
presence of obsessive/compulsive dimensions in the
worst-ever period of the disorder was evaluated using the
DY-BOCS scale41. Family psychiatric history was coded in
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percentages for each category, considering solely family
members who had received a formal diagnosis.
Treatment response
Treatment response was assessed by means of a
clinician-administered version of the Y-BOCS40. Patients
were assessed twice: at baseline and after 12 weeks at
maximum tolerated SRI doses, in both cases analyzing the
severity of obsessive and compulsive symptoms.
Stressful life event assessment
Life stress at onset of the disorder was analyzed using
the methodology described in Real et al.12. In face-to-face
interviews, patients were asked whether they could iden-
tify a SLE in the year prior to the onset of the disorder.
Patients reporting a SLE at onset were assigned to the
SLE-preceded OCD group, while the rest of the patients
formed the non-SLE-preceded OCD group. Patient-
reported SLEs at onset were contrasted with the Paykel
Scale of Stressful Life Events42 to conﬁrm that these
coincided with any of the 61 events listed on the scale.
Current treatment
Thirty-six (35.0%) of the 103 patients received SSRIs
(sertraline, ﬂuoxetine, ﬂuvoxamine, paroxetine, citalo-
pram or escitalopram) as monotherapy according to their
previous history of response. The remaining 67 (65.0%)
were administered clomipramine as monotherapy due to a
previous history of resistance to at least three SSRIs.
Genotyping data
All genotyping, quality control, and imputation proce-
dures were carried out on an original sample consisting of
433 OCD patients and 484 controls, and are described
elsewhere43. Genotypic data for cases and controls were
obtained using the Axiom Exome array (Affymetrix, Santa
Clara, CA, USA), following the manufacturer’s instruc-
tions. This panel includes 300 000 variants mainly from
coding regions (85%), a type of variation that contributes
disproportionately to single nucleotide polymorphism
(SNP) heritability44–46. Variant call was performed using
Affymetrix genotyping console software with the Axiom
GT1 algorithm.
Quality control procedures were carried out using
PLINK. SNPs that did not pass the following ﬁlters were
removed from the study: (i) genotyping call rate greater
than 95%; (ii) non-signiﬁcant departures from Hardy-
Weinberg equilibrium in control sample (P > 1 × 10−3);
(iii) non-signiﬁcant difference in call rate between cases
and controls (P > 1 × 10−3).
Composition of the polygenic risk score
In order to generate a discovery sample, 131 samples
that would constitute the target sample to study response
to treatment, were removed from the genotyping data set.
The target sample was selected considering the availability
of neuroimaging data from these patients for another
study currently underway. Then, an allelic association test
for OCD status was carried out on the discovery sample
using PLINK v1.0747, considering all the autosomal SNPs
at MAF > 5%. These SNPs were all included in the PRS
model. The PRS in the target sample was calculated as the
sum of every risk allele carried by an individual, weighted
according to its effect size, measured as the logOR (using
the score option in PLINK v1.07). Several different
P threshold, from 0.01 to 1 (that is, inclusion of all the SNPs)
were considered.
Statistical analyses
Variance analyses were carried out using generalized
linear models (GLM) to analyze the predictive power of
the PRS for treatment response, and subsequently, the
modulatory role of SLEs at onset in this relation. Basal
and post-treatment Y-BOCS scores (basal Y-BOCS and
post Y-BOCS) were included in the equation separately.
Basal Y-BOCS was considered an independent variable,
and post Y-BOCS, the dependent variable. An analysis of
post Y-BOCS distribution was performed in order to
select a link function for it in the GLM. The model was
adjusted for sex, age, history of pharmacological resis-
tance, age at onset, and family psychiatric history of OCD,
given the observed inﬂuence of these factors on OCD
phenotype and treatment response48–50. The Akaike
information criterion (AIC) was compared between the
different models executed in order to determine which
showed the best ﬁt to the data. Given the large differences
between the variables’ scales, all of them were standar-
dized in order to obtain interpretable results.
To rule out any possible correlation between the PRS and
the adjustment variables, variance analyses were carried out
(t-test/ANOVA or Pearson correlation according to the
qualitative or quantitative nature of the variables, respec-
tively). Different models were used to analyze the predictive
power of PRS for treatment response (Table 1). First, only
basal Y-BOCS was included as an independent variable in
order to analyze a possible association between both Y-
BOCS measures (Model 1, Table 1). Then, a new analysis
(Model 2, Table 1) was performed that included the PRS as
an independent variable together with basal Y-BOCS.
Model 2 was then readjusted for each of the eight above-
mentioned demographic and clinical variables (Model 3,
Table 1). Furthermore, since the PRS was built from OCD-
risk variants, we thought it might also predict disorder
severity51 (in addition to disease status: 52,43). Then, further
models were executed to analyze a possible association
between each of the Y-BOCS measures and the PRS
(Models 4 and 5, Table 1). When basal Y-BOCS was a
dependent variable (Model 5), its distribution was
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analyzed in order to select an appropriate link function in
the GLM.
With respect to SLEs at onset, the possibility of sig-
niﬁcant differences in PRS between those presenting a
SLE at onset or not was ruled out by means of a t-test.
Correlations between SLEs at onset and each demo-
graphic or clinical variable included in the models as
independent variables (including basal Y-BOCS), were
also tested using t-test analysis for continuous variables
and chi square tests, for categorical variables.
To explore the modulatory role of SLEs at onset in
treatment response, a new model was constructed that
included SLEs at onset as an independent variable toge-
ther with basal Y-BOCS and the PRS (Model 6, Table 1).
All analyses were performed using R software version
3.2.2 (R Foundation for Statistical Computing, Vienna,
Austria).
Results
Genotyping and quality control
Quality control ﬁltering yielded genotypic data from a
sample of 370 cases and 443 controls. The ﬁnal data set
consisted of a total of 38 305 SNPs at a frequency > 5% in
the total sample. Further details on application of the
quality control ﬁlters are given in Costas et al.43.
Comparison with previous GWAS
Our results were compared with the available data from
previous GWAS studies: SNPs at P < 01 × 10−3 in meta-
analysis of Stewart et al.53. and SNPs at P < 01 × 10−4 in
the study of Matthiesen et al.54. None of the 33 SNPs
reported by Matthiesen et al. were presented in our
samples. Forty-four SNPs present in our samples are
among the 601 reported by Stewart et al. Two of them are
at P < 0.05 in our samples, but only one, rs6845865,
showed the same direction of association.
Polygenic risk score
A PRS was constructed for a total of 37 523 autosomal
SNPs associated to OCD status in the discovery sample.
One-hundred and three from the original 131 patients
conformed the ﬁnal target sample.
Treatment response
Three patients out of the 103 that constituted the target
sample did not complete the 12-week treatment. Then,
treatment response was obtained for a ﬁnal sample of 100
patients (44 females; mean age 33.42 ± 9.67) (Table 2).
The Patients’ scores on the Y-BOCS scale before and after
the treatment period are shown in Table 3.
Regression analyses were carried out in a ﬁnal sample
of 100 patients, for which treatment response was
obtained.
Polygenic risk score prediction ability
The main results are summarized in Table 4. Variance
analysis for the PRS and adjustment variables did not
reveal any signiﬁcant results. Basal Y-BOCS was a sig-
niﬁcant predictor of post Y-BOCS (Models 1 and 2;
Table 4, Supplemental Figure S1), even when including
the adjustment variables. Among these latter, only age
was a signiﬁcant predictor of post-treatment Y-BOCS
(Model 3, Table 4). However, age did not maintain its
predictive power when the rest of the adjustment vari-
ables were included in the model (P= .11). The PRS
was not a predictor of post Y-BOCS in any of these
models.
Although the models barely differed from one another,
Model 3 showed the best ﬁt (AIC= 205.691) and
explained the highest proportion of variance (R2= .581;
adj. R2= .568) (Table 4). Considering that Model
3 seemed the best model and the PRS was not a predictor
of post Y-BOCS, a new model was tested removing the
PRS and maintaining age as an independent variable
(Supplemental Table S1). The AIC for this new model was
lower than that for Model 3 (Table 4), presenting a better
ﬁt and explaining a relatively similar percentage of the
variance (R2= .575; adj. R2= .566).
In light of the above, the PRS was regressed on both Y-
BOCS measures separately. The PRS seemed to sig-
niﬁcantly predict both post and basal Y-BOCS (Table 5).
The AIC for Model 4 (AIC= 283.494) was higher than
that for all previous models, thus showing a worse ﬁt and
explaining quite a low percentage of variance compared
with the previous models (R2= .052; adj. R2= .043)
(Table 5).
SLE at onset modulation ability
Of the ﬁnal target sample of 100 patients, 40 (40%) were
categorized as SLE-preceded OCD and 60 (60%) as non-
SLE-preceded OCD.
ANOVA analyses of the PRS and SLEs at onset revealed
signiﬁcant differences in the PRS between those reporting
a SLE at onset of the disorder and those who did not (t=
Table 1 Models analyzing predictors for treatment
response
Model 1 Post Y-BOCS ~ Basal Y-BOCS
Model 2 Post Y-BOCS ~ Basal Y-BOCS+ PRS
Model 3 Post Y-BOCS ~ Basal Y-BOCS+ PRS+ Adjustments
Model 4 Post Y-BOCS ~ PRS
Model 5 Basal Y-BOCS ~ PRS
Model 6 Post Y-BOCS ~ Basal Y-BOCS+ PRS+ SLE
Model 7 Post Y-BOCS ~ Basal Y-BOCS+ PRS+ SLE+ Adjustments
Y-BOCS Yale–Brown obsessive-compulsive scale, PRS polygenic risk score, SLE
stressful life event
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2.96; df= 98; P= .004). In addition, signiﬁcant associa-
tions were found between a SLE at onset and age at onset
(t= 2.29; df= 98; P= .024) and sex (χ2= 4.93; df= 1; P
= .039). These results are shown in Supplemental Tables
S2 and S3.
According to the modulation analysis, a SLE at onset
was not a predictor for post Y-BOCS when considering
basal Y-BOCS and the PRS (B= -0.02; 95% CI, -0.29 to
0.26; P= .911), nor when any of the adjustment variables
were included.
Table 2 Sodiodemographic and clinical characteristics of the sample of 100 OCD patients
Age, Years, Mean ± SD (Range) 33.42 ± 9.67 (18–57)
Male/Female, n (%) 56/44 (56.0%, 44.0%)
Age at Onset of OCD, Mean ± SD (Range) 21.62 ± 10.03 (6–70)
Baseline Y-BOCS Score, Mean ± SD (Range)
Global 26.26 ± 5.16 (11–36)
Obsessions 13.12 ± 3.24 (0-26)
Compulsions 12.98 ± 2.99 (0- 19)
Baseline HDRS, Score, Mean ± SD (Range) 12.7 ± 5.05 (2–28)
Current Comorbid Diagnosis, n (%)
No comorbid disorder 53 (53.0)
Other Anxiety Disorder 10 (10.0)
Mood Disorder 9 (9.0)
Tics 3 (3.0)
Eating Disorders 2 (2.0)
Other 23 (23.0)
Presence of Dimensions in worst-ever period n (%)
Aggresive/checking 70 (70.0)
Symmetry/Ordering 43 (43.0)
Contamination/cleaning 49 (49.0)
Hoarding 26 (26.0)
Miscelaneos 32 (32.0)
History of Pharmacological Resistance n (%)
1 SSRI 27 (27.0)
2 SSRIs 12 (12.0)
>2 SSRIs 61 (61.0)
Family Psychiatric History n (% of patients) 1st grade 2nd grade 3rd grade Total
No psychiatric diagnosis 47 (47.0) 38 (38.0) 80 (80.0) 30 (30.0)
OCD 2 (2.0) 11 (1.0) 1 (1.0) 10 (10.0)
Subclinic OCD 6 (6.0) 5 (5.0) 1 (1.0) 12 (12.0)
Anxiety disorder different from OCD 13 (13.0) 4 (4.0) 0 (0.0) 15 (15.0)
Mood disorder 14 (14.0) 28 (28.0) 1 (1.0) 28 (28.0)
Psychotic disorder 5 (5.0) 5 (5.0) 8 (8.0) 13 (13.0)
Drug abuse 8 (8.0) 2 (2.0) 3 (3.0) 10 (10.0)
Eating disorder 1 (1.0) 0 (0.0) 0 (0.0) 1 (1.0)
Tics/ Guilles de la Tourette 2 (2.0) 5 (5.0) 4 (4.0) 9 (9.0)
Others 2 (2.0) 2 (2.0) 2 (2.0) 5 (5.0)
OCD obsessive-compulsive disorder, Y-BOCS Yale–Brown obsessive-compulsive scale, HDRS, Hamilton depression rating scale
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Discussion
This study was conducted to analyze if a PRS composed
of OCD-risk genetic variants predicted treatment
response in a sample of OCD patients, and whether this
relation was modulated by SLEs at onset. According to the
main regression analysis, the PRS did not predict treat-
ment response, and basal Y-BOCS was the best predictor
of post Y-BOCS in all cases. Only age, out of all the
adjustment variables, showed a predictive capacity for
treatment response, as those models that included it
presented the best ﬁt. An analysis of OCD severity indi-
cated that the PRS was a predictor of both basal and post
Y-BOCS. The results of a modulation analysis suggested
that SLEs at onset did not play a signiﬁcant role in
treatment response when considering the PRS. Differ-
ences in SLE at onset prevalence were observed for the
PRS, sex, and age at onset, whereby patients with a higher
genetic risk, women, and those presenting a later age at
onset were more likely to report a SLE at onset.
With respect to the regression analysis, PRS was not a
predictor for treatment response in our sample. Some
evidences exist about the non-shared genetic bases of
OCD risk and OCD treatment response22,55. In addition,
although other studies have found an association between
OCD treatment response and genes previously associated
to OCD risk14,15,19 (such as SLC1A1, SLC6A4 or
BDNF12,13), to our knowledge, only one genetic variant
(rs3087879 in SLC1A1 gene) has been related to both
OCD treatment response (a greater resistance) and OCD
risk12. We do not know to what extent this is due to
different genetic bases of treatment response and OCD
risk, since the variants studied in candidate gene asso-
ciation studies for OCD risk do not usually coincide with
those studied for treatment response. Studies of other
psychiatric disorders such as depression have also repor-
ted conﬂicting results regarding shared genetic bases for
etiology and treatment response56–62. Furthermore, some
of the variants found to be associated with both MDD risk
and antidepressant response do it in the same direction
(More MDD risk and worse treatment response) while
others do it in the opposite (More MDD risk and better
response)60. Furthermore, PRS composed of risk genetic
variants have also yielded inconsistent results as regards
predicting SSRI treatment response in MDD
patients26,27,63.
It is also important to note the role that pharmacoki-
netic variants apparently play in treatment response20,21.
These are not speciﬁcally considered in PRS methodology
since PRS composition is normally derived from GWAS
performed in relation to phenotype rather than treatment
response. In this regard, it might be interesting to analyze
the predictive power of a PRS composed of response-
associated rather than risk-associated variants, since these
may be not the same. Further analyses of shared and non-
shared genetic bases for OCD risk and treatment response
Table 3 Y-BOCS scores before and after 12-week
treatment period
Y-BOCS Score, Mean ± SD (Range)
Basal YBOCS Post YBOCS
Global 26.26 ± 5.16 (11–36) 19.18 ± 6.80 (6–36)
Obsessions 13.12 ± 3.24 (0–26) 9.49 ± 3.46 (3–18)
Compulsions 12.98 ± 2.99 (0–19) 9.57 3.60 (0–18)
Y-BOCS Yale–Brown obsessive-compulsive scale
Table 4 Predictors for treatment response
Model 1. Post Y-BOCS regressed on
Basal Y-BOCS
Model 2. Post Y-BOCS regressed
on Basal Y-BOCS and PRS
Model 3. Post Y-BOCS regressed on
Basal Y-BOCS, PRS and Age.
B CI p B CI p B CI p
(Intercept) −2.04E-16 −0.13 to 0.13 1.000 0.01 −0.13 to 0.13 1.000 −3.83E-17 −0.13 to 0.13 1.000
Basal Y- BOCS 0.74 0.61 to 0.87 <.001* 0.73 0.60 to 0.87 <.001* 0.75 0.62 to 0.89 <.001*
PRS 0.04 −0.10 to 0.18 .552 0.03 −0.11 to 0.16 .691
Age 0.17 0.04 to 0.30 .009*
Observations 100 100 100
R2/adj. R2 .551/.547 .553/.544 .581/.568
AIC 208.677 210.324 205.691
The predictive abilities of Basal YBOCS, PRS and Age for Post YBOCS arepresented as Beta coefﬁcients (β) from the regressions as well as with theproportion of
variance explained by the models (R2/Adj. R2). The model ﬁt isalso reported by the Akaike Information Criterion (AIC). Y-BOCS Yale-Brown obsessive-compulsive scale,
PRS polygenic risk score. *p < 0.05
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will be necessary to enable the design of personalized
pharmacological guidelines for OCD in the future.
Our results regarding PRS associations with basal and
post Y-BOCS were as expected, since a wide variety of
genetic variants have been associated with a higher risk of
OCD. Some of these variants are related to general ner-
vous system structure and function (DISP1, SLC1A1,
SLEC6A3, DRD3, 5HT3, BDNF:14-17,64), neurodevelop-
ment (NGFR and CDH9:17), neuroendocrinology
(NR3A1:65), and mitochondrial functioning-related oxi-
dative stress (MnSOD and UCP-2 genes:66). Hence, it was
expected that a PRS that combines numerous risk variants
would predict OCD severity in a sample of patients.
Similarly, a PRS composed of risk genetic variants for
schizophrenia has emerged as a good predictor of OCD43.
The associations found between the PRS and both basal
and post Y-BOCS seem to suggest that the PRS has the
capacity to predict disorder severity independently of
pharmacological intervention.
It is important to note that given the predictive capacity
of PRS for basal Y-BOCS, including both of them as
predictors of post Y-BOCS is statistically redundant.
However, including the PRS reduces the model’s statis-
tical strength; thus, Model 2 (Table 4) presented a worse
ﬁt (AIC= 210.324) than the model that did not include
the PRS (Model 1, Table 4; AIC= 208.677). Hence,
despite the collinearity of both the PRS and basal Y-
BOCS, since including the PRS makes the model statis-
tically weaker, Model 1 is a better predictive model than
Model 2.
Our ﬁndings regarding the predictive power of age for
treatment response agree with previous results associating
a greater age at treatment with a worse response to
SSRIs48. In addition, the models including age as a pre-
dictor (Model 3, Table 4; Table S1) showed the best ﬁt
(AIC: 205.691; AIC: 203.849). This suggests that age
might be an important factor in predicting treatment
response in OCD.
A worse response in older OCD patients could indi-
cating a negative correlation between age and neuro-
plasticity, since it is well known that therapeutic effects of
SRI are mediated by neuroplasticity mechanisms and that
this decays with age67,68. Then, SRI-induced neuroplasti-
city might not be as optimal in older patients when
compared to younger ones. Further research should be
developed to clarify this.
As opposed to our results, other studies found response
to coadjuvant risperidone in SRI-treated OCD patients to
present a positive correlation with age69. This might point
out to the speciﬁcity of our ﬁndings for SRI monotherapy.
Future research is required to conﬁrm the predictive
capacity of age for treatment response, since it could be an
important predictor to account for in OCD-treatment.
Analyses of the modulatory role of SLEs at onset
showed that these were non-predictors for treatment
response when included in the model. However, t test
analyses revealed differences in the PRS between those
reporting and not reporting a SLE at onset. One expla-
nation for this apparent association might be that patients
presenting a higher genetic risk for OCD could be more
prone to developing the disorder when a SLE occurs.
Thus, by itself, a SLE at onset may be insufﬁcient to
trigger OCD, but could play a role when other risk factors,
such as genetic risk, already exist. Nonetheless, most
authors have interpreted SLEs at onset as a reﬂection of
environmentally-explained OCD12. Furthermore, com-
pared to SLE-preceded patients, patients not reporting a
SLE at onset tend to present a higher frequency of certain
clinical characteristics, such as early age at onset or a
family history of OCD70, which have been attributed to
genetic factors71–73. These genetic factors might include
rare variants with a larger effect than the common var-
iants considered in the PRS, and therefore would not have
been captured by our model. Further research is required
to clarify the extent to which a SLE at onset can by itself
trigger OCD, and to elucidate the real role that SLEs at
Table 5 PRS predictive ability for YBOCS scores
Model 4. Post-YBOCS regressed on PRS Model 5. Basal Y-BOCS regressed on PRS
β CI p β CI p
(Intercept) −4.37E-16 −0.19 to 0.19 1.000 −3.18E-16 −0.19 to 0.19 1.000
PRS 0.23 0.04 to 0.42 .020* 0.25 0.06 to 0.44 .009*
Observations 100 100
R2 / adj. R2 .052 /.042 .064 /.055
AIC 283.494 282.118
The predictive abilities of PRS for Post and Basal Y-BOCS are displayed as Beta values (β) from the regressions and the proportions of variance explained by the models
(R2/Adj. R2). The model ﬁt is also reported by the Akaike Information Criterion (AIC)
Y-BOCS Yale–Brown obsessive-compulsive scale, PRS polygenic risk score
*p < .05
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onset may play in OCD etiology. Furthermore, although
pathogenesis and treatment response in OCD are now
relatively well established74,75, the respective inﬂuence of
environmental and genetic factors in triggering OCD
remains unclear.
It would also be interesting to analyze the modulatory
role of other kinds of environmental factors that have
consistently been shown to inﬂuence the development of
OCD, such as lifetime76 or childhood77–79 trauma. These
environmental factors have also been shown to modify the
inﬂuence exerted by genetic risk on OCD76. Our results
suggest that patients presenting a more neutral genomic
proﬁle could have an environmentally-explained OCD, in
which other environmental factors not yet analyzed might
be involved in development of the disorder.
Our results concerning SLE associations with age at
onset are in agreement with those reported in previous
studies, in which non-SLE-preceded patients presented an
earlier age of onset67,80. In addition, other studies have
also found a higher rate of women reporting a SLE at
onset80,81. This outcome agrees with the literature sug-
gesting that women are more vulnerable to trauma
experiences than men82,83.
This study presented some limitations. For example, the
size of the discovery (n= 370 cases; 443 controls) and
target sample (n= 100) was probably insufﬁcient in terms
of statistical strength to enable identiﬁcation of possible
associations84. In addition, the target sample presented a
somewhat low variability, since it consisted of patients
already treated with at least one SSRI. We don’t know if
results would have been different in naïve patients with-
out a history of resistance to pharmacological treatment.
In the analysis of SLE modulation, the dichotomic nature
of our environmental variable might have hindered
identiﬁcation of signiﬁcant associations. Inclusion of an
environmental factor that could be treated as a quanti-
tative variable would enable a richer analysis and facilitate
identiﬁcation of a possible modulatory role.
This is the ﬁrst study to explore the predictive power of
an OCD-risk PRS for treatment response in OCD
patients. Our goal was to shed light on the role that
polygenic risk may play in treatment response in OCD
probands, and the inﬂuence of a SLE at onset. Despite the
reduced sample size and our negative results on PRS
predictive value, some important ﬁndings arise from our
study. First, the conﬁrmation of age as inﬂuencing treat-
ment response should state the importance of early OCD
detection and treatment as essential. Secondly, we think
that the study of the genetic predictors of SRI response
should be expanded to other variants more than those
implicated in the risk for affective and anxiety disorders,
such as those involved in processes as neuroplasticity or
drug-metabolism, while assuming the transdiagnostic
aspect of SRI response. Understanding the factors that
inﬂuence treatment response will enable the development
of more individualized treatments that yield a better
response and reduce secondary effects and the dropout
rate. Further research will be necessary to elucidate the
genetic and environmental bases of treatment response in
OCD.
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